ARCHIVES

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

This article is from The Cancer Letter archive.

Vol. 31 No. 02 | January 14, 2005

Download PDF Visit The Full Archive

Related Articles

FDA IND Approval Of New Cancer Drug Is First Based On Phase 1 Clinical Trials In Europe

December 5, 1986

Karen Antman recruited to NCI on an IPA to oversee changes to centers, SPORE programs.

October 31, 2003

Army Breast Cancer Research Program Seeks Proposals

March 28, 1997

“Do What’s Right for People With Cancer”. Glick’s Credo

May 24, 1996

Univ. Of Washington, Fox Chase, ICC Win CCRU, CCSP Awards

July 8, 1983

In Brief: Univ. of Texas Panel Selects Four finalists for M.D. Anderson Cancer Center Presidency

April 19, 1996